More Stories

Informist, Tuesday, Feb. 3, 2026

By P. Madhu Kumar and Shakshi Jain

MUMBAI/NEW DELHI – In race to make the most out of the opportunity presented by semaglutide generic, Mankind Pharma Ltd.'s management Tuesday said the company is on track to launch the glucagon-like peptide-1 product towards the end of March, the same as its peers. The patents of semaglutide brands Ozempic and Wegovy expire in March across major markets like India, China, and Brazil, which is expected to unlock a massive opportunity for generic drug makers.

Expiry of the patents will give generics easy access to the market, likely reducing prices of the drug by up to 80% and creating a substantial, multi-billion-dollar market for affordable diabetes and obesity care, according to experts. 

In a post-earnings conference call with analysts, Mankind Pharma's management said it will take another two to three years for it to penetrate the rest of the world markets and it expects to enter those regions by 2029-30. The company is primarily focussed on the domestic market and it will not compromise on its earnings before interest, tax, depreciation, and amortisation for expansion in the overseas markets, the management said.

The company's domestic business contributes the most to its revenue from operations. It accounted for over 85% of the company's consolidated top line for the December quarter at INR 30.46 billion, reflecting an increase of 11% on year.

Mankind Pharma reported a consolidated net profit of INR 4.09 billion for the December quarter, up nearly 8% on year but lower than analysts' expectations of INR 4.76 billion. The company incurred a one-time cost of INR 1.07 billion, of which INR 741 million was due to the implementation of labour codes, INR 190 million was due to costs related to intellectual property rights, and the remaining was from an asset impairment provision. The company's consolidated revenue for the quarter was INR 35.67 billion, up nearly 12% on year. more

The company's management expects to register a sequential growth in its anti-infective segment in the upcoming quarters. The anti-infective segment falls under the company's acute therapy portfolio and it is a significant contributor to its sales within the category. The company reported a muted growth for the December quarter in its anti-infective segment and the management said they are taking steps to improve the performance of the segment. It also expects an improvement in the sales of over-the-counter drugs "soon", which were subdued since past few quarters.

Talking about the challenges faced in the previous quarters, the management said it saw high employee attrition but the situation is now returning to normalcy. "Whenever any kind of a mission happens and people are being asked to leave, some kind of insecurity creeps in people's mind. So, in this process, good people also went," the management explained.

During the December quarter, the company registered a mid-single-digit organic growth in exports, the management said. The company's research and development cost in Oct-Dec was 2.9% of sales, which partially impacted the adjusted EBITDA margin, contracting 170 basis points on year to 25.9%.

The company announced its December quarter earnings post market hours. Tuesday, the stock ended nearly 5% higher at INR 2,162.60 on the National Stock Exchange. End

Edited by Ashish Shirke

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.